For MBM, loss of antigen presentation and enrichment of type-2 immunity suggest TGFβ blockade and upregulation of cytotoxic natural killer (NK) cell-mediated or CD4+ T cell-mediated anti-tumor immunity33 as potential therapeutic strategies. This evidence concerns the gene TGFB1 and neoplasm.